Larimar Therapeutics Valuation
| LRMR Stock | USD 2.54 0.03 1.20% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Larimar Therapeutics secures a last-minute Real Value of $2.44 per share. The latest price of the firm is $2.54. Our model forecasts the value of Larimar Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.44, shares owned by insiders of 1.71 %, and Current Valuation of (36.91 M) as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Larimar Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Larimar Therapeutics is based on 3 months time horizon. Increasing Larimar Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Larimar stock is determined by what a typical buyer is willing to pay for full or partial control of Larimar Therapeutics. Since Larimar Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Larimar Stock. However, Larimar Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.54 | Real 2.44 | Hype 2.54 | Naive 2.57 |
The intrinsic value of Larimar Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Larimar Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Larimar Therapeutics helps investors to forecast how Larimar stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Larimar Therapeutics more accurately as focusing exclusively on Larimar Therapeutics' fundamentals will not take into account other important factors: Larimar Therapeutics Total Value Analysis
Larimar Therapeutics is now expected to have valuation of (36.91 M) with market capitalization of 162.07 M, debt of 5.55 M, and cash on hands of 54.92 M. The negative valuation of Larimar Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Larimar Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(36.91 M) | 162.07 M | 5.55 M | 54.92 M |
Larimar Therapeutics Asset Utilization
One of the ways to look at asset utilization of Larimar is to check how much profit was generated for every dollar of assets it reports. Larimar Therapeutics secures a negative usage of assets of -0.29 %, losing $0.002855 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Larimar Therapeutics shows how discouraging it operates for each dollar spent on its assets.Larimar Therapeutics Ownership Allocation
The majority of Larimar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Larimar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Larimar Therapeutics. Please pay attention to any change in the institutional holdings of Larimar Therapeutics as this could imply that something significant has changed or is about to change at the company.Larimar Therapeutics Profitability Analysis
Net Loss for the year was (36.95 M) with profit before overhead, payroll, taxes, and interest of 0.About Larimar Therapeutics Valuation
The stock valuation mechanism determines Larimar Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Larimar Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Larimar Therapeutics. We calculate exposure to Larimar Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Larimar Therapeutics's related companies.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreichs ataxia, a rare, progressive, and fatal genetic disease. Larimar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people.
Larimar Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Larimar Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 43.9 M |
Additional Tools for Larimar Stock Analysis
When running Larimar Therapeutics' price analysis, check to measure Larimar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Larimar Therapeutics is operating at the current time. Most of Larimar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Larimar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Larimar Therapeutics' price. Additionally, you may evaluate how the addition of Larimar Therapeutics to your portfolios can decrease your overall portfolio volatility.